secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvalent, Inc. (NUVL)
CIK:        0001861560
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0000950170-24-093278
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvalent reports $658M cash, FDA breakthrough therapy for two candidates, net loss $57.2M in Q2
--------------------------------------------------------------------------------

- Cash, equivalents and securities $658.0M as of June 30, 2024; operating runway into 2027.
- Net loss $57.2M for Q2 2024; R&D expense $49.2M, G&A $16.0M.
- FDA breakthrough therapy designation for zidesamtinib (ROS1) and NVL-655 (ALK).
- Phase 2 enrollment ongoing for ALKOVE-1 (NVL-655) and ARROS-1 (zidesamtinib) with registrational intent; ESMO updates September 14.
- Initiated HEROEX-1 Phase 1a/1b trial for NVL-330 in HER2-altered NSCLC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1861560/000095017024093278/0000950170-24-093278-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1861560/000095017024093278/nuvl-20240808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-093278

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer